imatinib mesylate has been researched along with Cryptogenic Fibrosing Alveolitis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H | 1 |
| Aono, Y; Azuma, M; Kishi, M; Nishioka, Y | 1 |
| Chilakapati, DR; Chilakapati, SR; Kanala, JR; Serasanambati, M; Vissavajjhala, P | 1 |
| Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G | 1 |
| Daniels, CE; Gabor, E; Lasky, JA; Limper, AH; Mieras, K; Schroeder, DR | 1 |
2 review(s) available for imatinib mesylate and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis.
Topics: Alveolar Epithelial Cells; Animals; Benzamides; Disease Models, Animal; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2013 |
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin | 2016 |
1 trial(s) available for imatinib mesylate and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Topics: Aged; Anemia; Benzamides; Disease Progression; Double-Blind Method; Dyspnea; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematoma, Subdural; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Leukopenia; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2010 |
2 other study(ies) available for imatinib mesylate and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2018 |
Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib.
Topics: Actins; Animals; Anti-Inflammatory Agents; Bleomycin; Bosentan; Catalase; Collagen Type I; Collagen Type II; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Lung; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Oxidative Stress; Peroxidase; Pneumonia; Pulmonary Edema; RNA, Messenger; Sulfonamides; Superoxide Dismutase; Time Factors | 2015 |